Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor

Archives of Ophthalmology

Volumn 117, Issue 4, 1999, Pages 498-503

  Das, Arup ^a,b   McLamore, Angela ^a   Song, Wanmin ^a   McGuire, Paul G ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; UROKINASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HISTOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

EID: 0032955659     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.117.4.498     Document Type: Article

References (32)

1. Frank RN, Das A. Pathogenic mechanisms in diabetic eye diseases. In: Feman SS, ed. Ocular Problems in Diabetes Mellitus. Boston, Mass: Blackwell Scientific Publications; 1992:95-133.
2. Frank RN. On the pathogenesis of diabetic retinopathy: 1990 update. Ophthalmology. 1991;98:586-593.
3. D'Amore PA. Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci. 1994;35:3974-3979.
4. Casey R, Li WW. Factors controlling ocular angiogenesis. Am J Ophthalmol. 1997; 124:521-529.
5. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
6. Aiello LP. Vascular endothelial growth factor: 20th century mechanisms, 21st century therapies. Invest Ophthalmol Vis Sci. 1997;38:1647-1652.
7. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LEH. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92:905-909.
8. Pepper MS, Montesano R. Proteolytic balance and capillary morphogenesis. Cell Differ Dev. 1990;32:319-327.
9. Mignati P, Rifkin DB. Plasmonogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein. 1996;49:117-137.
10. Pepper MS, Belin D, Montesano R, Orci L, Vassali JD. Transforming growth factor β-1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol. 1990;111: 743-755.
11. Pepper MS, Vassali JD, Wilks JW, et al. Modulation of microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J Cell Biochem. 1994; 55:419-434.
12. Smith LEH, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
13. Smith LEH, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 1997;276:1706-1709.
14. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of VEGF using a VEGF-receptor chimeric protein. Proc Natl Acad Sci U S A. 1995;92:10457-10461.
15. Robinson GS, Pierce EA, Rook SL, et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci U S A. 1996;93:4851-4856.
16. Davies B, Brown PD, East N, et al. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 1993;53:2087-2091.
17. Botos I, Scapozza L, Zhang D, et al. Batimastat, a potent matrix metalloproteinase inhibitor, exhibits an unexpected mode of binding. Proc Natl Acad Sci U S A. 1996;93:2749-2754.
18. Schnaper HW, Grant DS, Stetler-Stevenson WG, et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol. 1993; 156:235-246.
19. Chirivi RGS, Garofalo A, Crimmin MJ, et al. Inhibition of the metastatic spread and growth of B 16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer. 1994;58:460-464.
20. Wojtowicz-Praga S, Low J, Marshall J, et al. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs. 1996;14:193-202.
21. Freidman R, Toth M, Pena D, Mobashery S. Activation of progelatinase B (MMP-2) by gelatinase A (MMP-2). Cancer Res. 1995;55:2548-2555.
22. Das A, McGuire PG, Eriqat C, et al. Expression of urokinase and matrix metalloproteinases is increased in clinical and experimental retinal neovascularization. Invest Ophthalmol Vis Sci. 1997;38(suppl):S964.
23. Jackson DW, McGuire PG, Eriqat C, Das A. Both vascular endothelial growth factor (VEGF) and hypoxia increase gelatinase A (MMP2) activity in vascular endothelial cells in vitro. Invest Ophthalmol Vis Sci. 1997;38(suppl):S500.
24. Wei Y, Waltz DA, Rao N, et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem. 1994;269:32380-32388.
25. Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem. 1994;269:14746-14750.
26. Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science. 1996;273:1551-1556.
27. Blasi R. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays. 1993;15:105-111.
28. Rabhani SA, Desjardins J, Bell AW, et al. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun. 1990;173:1058-1064.
29. Brooks PC, Stronblad S, Sanders LC, et al. Localization of matrix metalloproteinases MMP-2 to the surface of invasive cells by interaction with integrin alpha v β 3. Cell. 1996;85:683-693.
30. Montgomery AMP, Reisfeld RA, Cheresh DA. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci U S A. 1994;91:8856-8860.
31. Adamis AP, Shima DT, Tolentino MJ. Inhibition of VEGF prevents ocular neovascularization in a non-human primate. Arch Ophthalmol. 1996;93:4851-4856.
32. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCB inhibition with LY333531. Invest Ophthalmol Vis Sci. 1998;39:171-179.